Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bioterrorism -- Ignore unavailable to you. Want to Upgrade?

To: Glenn Petersen who wrote (294)	10/18/2001 5:39:57 PM
From: Biomaven	Read Replies (1) \| Respond to of 891

Hunkered down in your end-of-the-world bunker with separate "male and female dormitories." Where's the fun in that? <g> On a more serious note, the FDA has finally pointed out that doxy works just fine for anthrax too: FDA reminds all health professionals and the general public that Doxycycline is approved for the treatment of anthrax in all its forms. The FDA is providing additional information concerning the dosing regimen for the treatment of anthrax, including cutaneous and inhalation anthrax (post-exposure). The currently recommended dosage regimen of doxycycline for severe disease is 100 mg every 12 hours for adults and 1mg per pound (2.2mg per kilogram) every 12 hours for children less than 100 pounds. These dosage regimens are appropriate for use in patients who have been exposed to anthrax (Bacillus anthracis) regardless of the route of exposure. To see the full Advisory text, go to fda.gov Peter